BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:The approval of the first anti-amyloid drugs has resurrected t he neurodegenerative disease space\, opening the door for enhanced compet ition and innovation to develop novel disease-modifying therapies. Howeve r\, as challenges remain in the clinical adoption of Lecanemab and Donane mab\, the field needs to navigate the move towards disease-modifying ther apeutics.\n\nCapitalizing on the surge of innovation across new targets\, lessons learned from clinical setbacks\, groundbreaking progress in bloo d-based diagnostics\, and more\, the 14th Alzheimer’s and Parkinson’s Dru g Development Summit returns as the only industry-focused and end-to-end meeting\, with comprehensive coverage spanning early discovery through to late clinical and regulatory.\n\n \;\n\nURLs:Tickets: https://go.evv nt.com/3259347-2?pid=185 \;Brochure: https://go.evvnt.com/3259347-3?p id=185 \;\n\nDate and Time: Tue\, 03 Feb 2026 08:00 - Thu\, 05 Feb 20 26 17:00\n\nVenue details: Hyatt Regency Boston Harbor\, 101 Harborside D rive\, Boston\, Massachusetts\, 02128\, United States\n\nCategory: Confer ences | Science\, Health &\; Medicine | Pharmaceuticals | Drug Develop ment\n\nPrices:Drug Developer Pricing - Conference + Pre-Conference Day: USD 3497.00\,Drug Developer Pricing - Conference Only: USD 2599.00\,Acade mic Pricing - Conference + Pre-Conference Day: USD 2897.00\,Academic Pric ing - Conference Only: USD 2199.00\,Solution Provider Pricing - Conferenc e + Pre-Conference Day: USD 5197.00\,Solution Provider Pricing - Conferen ce Only: USD 3799.00\n\nSpeakers: Ross Jeggo\, Head of Neurology Research \, Biogen\, Jessica Wu\, Scientific Director\, Biogen\, Achim Kless PhD\, Senior Director\, Discovery Neuroscience Research\, Neuroscience Genetic s\, Eli Lilly and Co.\, Dimitry Ofengeim\, Senior Scientist\, Head\, of D istinguished\, Neuroinflammation and Precision Neurology Group\, Sanofi\, Gennaro Pagano\, Group Leader and Expert Medical Director In Early Devel opment\, Roche\, Nellwyn Hagan\, Scientific Director Neurodegenerative Di sorders\, Takeda Pharmaceutical\, Gyan Srivastava\, Associate Director an d Head Of Computational Biology\, Alexion Pharma UK\, Malleswari Challagu ndla\, Senior Scientist II\, Abbvie\, Laura Cohen\, Vice President\, Alzh eimer's Environment Shaping\, Eli Lilly and Co.\, Abigail Mariga\, Senior Principal Scientist\, Bristol Myers Squibb\, Nima Shariati\, Project Sta tistician and Data Science Team Lead\, Roche\, Danielle Graham\, Vice Pre sident and Head of Biomarkers\, Biogen\, Roman Loonis\, Associate Medical Director\, Clinical Sciences\, Neurodegenerative Disorders\, Takeda Phar maceutical\, Eric Siemers\, Chief Medical Officer\, Acumen Pharmaceutical s\, Kira Holmström\, Head of Biomarker Research\, Herantis\, Bruce Morimo to\, Head\, Drug Development\, Fuku Biotech\, Lili Zhang\, Senior Vice Pr esident\, Head of Preclinical Development\, Aprinoia Therapeutics Inc.\, Paul Gregor\, Chief Executive Officer\, Gismo Therapeutics Inc.\, Raj Raj agovindan\, Vice President - Translational Medicine\, Voyager Therapeutic s\, Inc\, Paul Ashton\, President and Chief Executive Officer\, Inflammas ome Therapeutics\, Susan Abushakra\, Chief Medical Officer\, Alzheon\, Je nnifer Johnston\, Co-Founder and Chief Executive Officer\, NysnoBio\, Mar ianthi Papakosta\, Director\, Neuroscience Research\, Neurocrine Bioscien ces\, Patrick Kesslak\, Senior Research Fellow\, Alzheon\, Sathya Ganesan \, Director\, Global Regulatory Affairs\, UCB\, Yongchang Qiu\, Founder a nd Chief Executive Officer\, Lysoway Therapeutics\, Karen Quadrini\, Dire ctor\, Clinical Biomarkers\, Prothena Corporation\, Malú Tansey\, Directo r of Neuroimmunology Research and Executive Associate Director of Educati on Stark Neuroscience Research Institute\, Indiana University School of M edicine\, Alexander Shtilbans\, Director of Movement Disorder Program\, H SS\, Hospital for Special Surgery\; Assistant Professor of Neurology\, Co rnell University\, Pardeep Pabla\, Living with Parkinson's Disease\, Thar ick A Pascoal\, Assistant Professor\, UPitt\, Mira Chaurushiya\, Managing Director\, Westlake Village BioPartners\, Manik Kuchroo\, Investor\, Pol aris Partners Ltd\, Brendan Hussey\, Vice President\, JLS Fund\, Fernanda Cerqueira\, Senior Associate Director - Research Programs and Translatio nal\, The Michael J. Fox Foundation for Parkinson's Research\n DTEND:20260205T170000 DTSTAMP:20260512T220337Z DTSTART:20260203T080000 LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive \, Boston\, M assachusetts\, 02128\, SEQUENCE:0 SUMMARY:The approval of the first anti-amyloid drugs has resurrected the n eurodegenerative disease space\, opening the door for enhanced competitio n and inn... UID:0412ae36-dc9a-443b-b4b4-0d29a5aa5d76 END:VEVENT END:VCALENDAR